Brooks J, Baker G A, Aldenkamp A P
The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, L9 7LJ, Liverpool, UK.
Epilepsy Res. 2001 Mar;43(3):227-37. doi: 10.1016/s0920-1211(00)00198-4.
To provide further evidence of the reliability and validity of the ABNAS as a measure of patient-perceived cognitive side effects of antiepileptic drug treatment.
The measure was developed specifically to assess patient-perceived cognitive side effects of antiepileptic drug treatment. Evidence of its reliability and validity has been previously documented and this evidence has been further extended by administration of a battery of 400 questionnaires to two groups (200 people with epilepsy, PWE; and 200 controls who do not have epilepsy). The questionnaire packs consisted of the ABNAS, HADS, the everyday memory questionnaire, and the Adverse Events Profile. Data were analysed using MAP-R and SPSS.
Further evidence of the psychometric properties of the scale demonstrated that it had excellent reliability (Cronbach's alpha=0.96) and good face, congruent, content and construct validity. The sensitivity of the instrument was demonstrated through analysis of floor and ceiling levels.
The ABNAS is a reliable, tool for the detection of cognitive impairments associated with epilepsy and its treatment. We have provided further evidence of its criterion validity. This measure has the potential to be a useful tool for both clinical practice and clinical trials.
为ABNAS作为评估患者感知的抗癫痫药物治疗认知副作用的一种测量方法的可靠性和有效性提供进一步证据。
该测量方法是专门为评估患者感知的抗癫痫药物治疗认知副作用而开发的。其可靠性和有效性的证据先前已有记录，并且通过向两组（200名癫痫患者和200名非癫痫对照者）发放400份问卷进一步扩展了这一证据。问卷包包括ABNAS、医院焦虑抑郁量表（HADS）、日常记忆问卷和不良事件概况。使用MAP-R和SPSS对数据进行分析。
该量表心理测量特性的进一步证据表明，它具有出色的可靠性（克朗巴哈系数α=0.96）以及良好的表面效度、等值效度、内容效度和结构效度。通过分析地板效应和天花板效应水平证明了该工具的敏感性。
ABNAS是检测与癫痫及其治疗相关认知障碍的可靠工具。我们提供了其效标效度的进一步证据。该测量方法有可能成为临床实践和临床试验的有用工具。
